Activating mutations in Gaq proteins, which form the a subunit of certain heterotrimeric G proteins, drive uveal melanoma oncogenesis by triggering multiple downstream signaling pathways, including PLC/PKC, Rho/Rac, and YAP. Here we show that the small GTPase ARF6 acts as a proximal node of oncogenic Gaq signaling to induce all of these downstream pathways as well as b-catenin signaling. ARF6 activates these diverse pathways through a common mechanism: the trafficking of GNAQ and b-catenin from the plasma membrane to cytoplasmic vesicles and the nucleus, respectively. Blocking ARF6 with a small-molecule inhibitor reduces uveal melanoma cell proliferation and tumorigenesis in a mouse model, confirming the functional relevance of this pathway and suggesting a therapeutic strategy for Ga-mediated diseases.
In Brief
Yoo et al. report that oncogenic GNAQ, a Gaq protein, induces its multiple signaling pathways through a single node-ARF6. Blocking ARF6 with a small-molecule inhibitor reduces the growth of GNAQ-dependent uveal melanoma cells in vitro and in vivo, suggesting a therapeutic strategy for Ga-mediated diseases.
INTRODUCTION
Mutations that confer constitutive activity to G-protein-coupled receptors (GPCRs) or Ga proteins have been identified in numerous diseases, including human cancers (Dorsam and Gutkind, 2007; Marinissen and Gutkind, 2001; O'Hayre et al., 2014; O'Hayre et al., 2013) , McCune-Albright syndrome (Weinstein et al., 1991) , and Sturge-Weber syndrome (Nakashima et al., 2014; Shirley et al., 2013) . One such disease is uveal melanoma, in which over 80% of tumors harbor an oncogenic activating mutation in either of two Ga q class (Gaq) proteins: GNAQ and GNA11 (Van Raamsdonk et al., 2009; Van Raamsdonk et al., 2010) .
Uveal melanoma is the most common primary ocular malignancy, and there are no effective treatments for metastatic forms of this disease. The discovery of oncogenic GNAQ and GNA11 mutations in uveal melanoma has led to the identification of multiple downstream signaling pathways that could be targeted for therapeutic purposes (Shoushtari and Carvajal, 2014) . These signaling pathways include phospholipase C-b (PLC-b)/protein kinase C (PKC) and Rac1/RhoA, which lead to the activation of ERK, p38, JNK, and YAP and subsequent AP-1-and YAP/ TEAD-mediated transcription (Feng et al., 2014; Khalili et al., 2012; Vaque et al., 2013; Wu et al., 2012b; Yu et al., 2014) . However, it has been unclear how activating mutations in Gaq proteins exert their control over these divergent downstream pathways and whether activated Gaq proteins govern additional oncogenic pathways.
The small guanosine triphosphatase (GTPase) ADP-ribosylation factor 6 (ARF6) (Kahn and Gilman, 1984 ) is an attractive candidate as an effector of Gaq signaling. ARF6 is activated by a variety of different ARF-guanine nucleotide exchange factors (ARF-GEFs), depending on the stimulating factor or cell type. Heterologous expression studies in HEK293T cells have suggested that activated Gaq proteins associate with various ARF-GEFs, which leads to the activation of ARF6 (Giguere et al., 2006; Laroche et al., 2007) . Other studies have shown the crucial role ARF6 plays in invasion, metastasis, and proliferation of several different types of cancers (Grossmann et al., 2013; Hu et al., 2009 Hu et al., , 2012 Li et al., 2009; Morishige et al., 2008; Muralidharan-Chari et al., 2009) . ARF6 is a critical mediator of endocytosis and the recycling of multiple membrane receptors, including GPCRs and cadherin-catenin complexes (Chen et al., 2003; D'Souza-Schorey et al., 1995; HunzickerDunn et al., 2002; Palacios et al., 2001 ). We recently demonstrated that in human cutaneous melanoma cells, WNT5A stimulation of the GPCR FZD4 activates ARF6, which promotes the trafficking of b-catenin from its N-cadherin-bound membrane form to the nucleus where it stimulates TCF-mediated transcription (Grossmann et al., 2013) .
In this study, we investigate the role of ARF6 as a mediator of all known oncogenic signaling pathways that are controlled by activating GNAQ mutations. The mechanism of ARF6 action is examined by determining whether it regulates GNAQ and b-catenin trafficking in uveal melanoma cells. We also assess the efficacy of targeting ARF6 for therapeutic purposes in a murine orthotopic xenograft model of human uveal melanoma. Finally, we seek to provide a mechanistic framework for studying other cancers harboring activating Ga mutations and an alternative approach for identifying therapeutic targets for these cancers.
RESULTS

Oncogenic GNAQ Promotes ARF6 Activation to Control the Proliferation of Uveal Melanoma Cells
We investigated whether ARF6 might also be important in cancers harboring somatic activating mutations of Gaq, based on the reported role of ARF6 in several cancers (Grossmann et al., 2013; Hu et al., 2009 Hu et al., , 2012 Li et al., 2009; Morishige et al., 2008; Muralidharan-Chari et al., 2009 ) and studies showing that Gaq proteins can activate or signal through ARF6 (Bose et al., 2001; Giguere et al., 2006; Laroche et al., 2007) . We first examined ARF6 protein levels in human uveal melanomas that carried activating mutations in either GNAQ or GNA11. ARF6 protein levels were on average 1.7-fold higher in uveal melanomas than in normal choroid melanocytes isolated from eyes that were surgically removed due to uveal melanoma (Figure S1A) . We next tested whether GNAQ in Mel92.1 and Mel202 uveal melanoma cells was required for ARF6 activation. Mel202 and Mel92.1 cells carry GNAQ Q209L , a common activating mutation in GNAQ (Griewank et al., 2012; Van Raamsdonk et al., 2009) . The levels of ARF6-GTP were measured following GNAQ knockdown using two different small interfering RNAs (siRNAs). Each knockdown reduced ARF-GTP levels by greater than 50% compared with a negative control siRNA that lacks homology to any known mammalian gene ( Figure 1A ). Consistent with these results, HEK293T cells transfected with vectors expressing GNAQ Q209L exhibited elevated levels of ARF6-GTP whereas those cells expressing wild-type GNAQ did not ( Figure S1B ).
Knockdown of GNAQ in cultured uveal melanoma cells has been shown to inhibit cell growth (Van Raamsdonk et al., 2009) . To determine whether this inhibition is ARF6 dependent, we compared growth parameters between uveal melanoma cells transfected with siRNAs directed against ARF6 or GNAQ. Knockdown of ARF6 or GNAQ in both Mel92.1 and Mel202 cells caused similar reductions in cell proliferation and anchorageindependent colony growth ( Figures 1B-1D ). These results demonstrate a central role for ARF6 in oncogenic GNAQ-mediated cell proliferation.
To determine whether ARF6 activation can rescue reduced GNAQ expression, we expressed constitutively active ARF6 (ARF6 Q67L ) in Mel202 cells while knocking down GNAQ expression. Both cell proliferation and anchorage-independent colony growth were partially rescued by constitutively active ARF6 when GNAQ expression was knocked down (Figures S1C-S1E), suggesting that the activation of ARF6 may serve to enhance oncogenic GNAQ signaling, not replace it. Constitutively active ARF6 may act through the residual GNAQ present following GNAQ knockdown to partially rescue the function of GNAQ.
GNAQ Acts through ARF6 to Orchestrate Multiple Downstream Signaling Pathways
Signaling pathways stimulated by oncogenic GNAQ include those mediated by PLC-PKC and Rac/Rho (Feng et al., 2014; Vaque et al., 2013; Wu et al., 2012a; Yu et al., 2014) . Knockdown of either ARF6 or GNAQ in uveal melanoma cells resulted in a significant reduction in PLC activity ranging from 24% to 80% inhibition when using a phosphoinositide turnover assay (Figure 2A) . Consistent with this reduction in PLC activity, the level of phosphorylated myristoylated alanine-rich C-kinase substrate (p-MARCKS), a substrate of PKC, was decreased by ARF6 knockdown ( Figures 2B and S2A ). Knockdown of ARF6 or GNAQ also significantly reduced the levels of Rac1-GTP/ RhoA-GTP and their downstream readouts, phosphorylated ERK, p38, JNK, and c-jun ( Figures 2C-2E and S2B-S2G). The reduction of c-jun phosphorylation resulted in decreased AP-1 transcriptional activity ( Figure 2F ).
Oncogenic GNAQ enhances nuclear YAP activation through Rac1/RhoA, implicating YAP as a potential therapeutic target for uveal melanoma (Feng et al., 2014; Yu et al., 2014) . Silencing ARF6 or GNAQ inhibited by 60% the nuclear localization of YAP in uveal melanoma cells, as detected by immunocytofluorescence and subcellular fractionation/immunoblotting (Figures 2G, 2H, and S2H) . mRNA levels of the YAP target genes CYR61 and CTGF were also reduced in Mel92.1 and Mel202 cells in which ARF6 was knocked down ( Figure 2I ). ) show individual data points normalized to control along with geometric mean and 95% confidence interval (95% CI). 95% CIs that do not cross the dotted line at y = 1 represent significant differences relative to the control at a = 0.05. n = 3. Data in (B) and (C) represent mean ± SD. ***p < 0.001, one-way ANOVA, Dunnett's multiple comparisons test. See also Figure S1 .
The finding that ARF6 is an effector of oncogenic GNAQ that activates multiple signaling pathways suggested that constitutively active ARF6 (ARF6   Q67L   ) would also activate these same pathways. Ectopic expression of ARF6 Q67L or GNAQ Q209L in HEK293T cells induced the PLC-PKC and MAPK pathways, including the activation of ERK, p38, JNK, and c-jun and the increase in AP-1 transcriptional activity, YAP nuclear accumulation, and YAP-mediated transcription ( Figures S2I-S2N ). These results show that ARF6 is both necessary and sufficient, at least in cells expressing endogenous wild-type Gaq proteins, to mediate GNAQ activity, and thus serves as a critical signaling node. However, based on the partial functional rescue that we achieved with constitutively active ARF6 following GNAQ knockdown in uveal melanoma cells and previous reports showing that Gaq proteins directly bind to and activate PLC-b1 (Berstein et al., 1992; Blank et al., 1991) , we propose that activated ARF6 enhances GNAQ signaling and cannot entirely replace it. relocalization of b-catenin from the membrane to the nucleus to induce b-catenin-mediated transcription and cancer cell invasion and metastasis (Grossmann et al., 2013) . We therefore examined whether the oncogenic GNAQ-activated ARF6 also increased the translocation of b-catenin from the membrane to the nucleus in uveal melanoma cells. Knocking down GNAQ or ARF6 in uveal melanoma cells resulted in an increase in the membrane pool of b-catenin and a corresponding decrease in the cytosolic and nuclear pools, as shown by both immunocytofluorescence and subcellular fractionation analyses ( Figures 3A  and 3B ). These treatments also significantly reduced luciferase activity in a 7TFP-mediated luciferase reporter assay (a measure of b-catenin-mediated transcription) ( Figure 3C ). Knockdown of GNAQ and ARF6 did not alter total b-catenin protein levels (Figure S3A) , suggesting that the mechanism that controls b-catenin intracellular localization by GNAQ Q209L -activated ARF6 is independent of the mechanism of b-catenin stabilization by WNTs. In HEK293T cells, ectopic expression of ARF6 Q67L or GNAQ
Q209L
decreased the membrane pool of b-catenin and concomitantly increased the cytosolic and nuclear pools of b-catenin (Figure S3B) . These same active forms of ARF6 and GNAQ also increased the activity of a b-catenin-responsive luciferase reporter ( Figure S3C ). Together, these results show that an oncogenic Gaq protein induces b-catenin signaling and that it does so through the activation of its effector ARF6, which promotes the relocalization of b-catenin from the plasma membrane to the nucleus. Other investigators have shown that ERK activation induces casein kinase 2 (CK2)-mediated phosphorylation of a-catenin, which destabilizes adherens junctions and releases b-catenin from cadherins (Ji et al., 2009; Pellon-Cardenas et al., 2013) , and that this activation can be induced by ARF6 in epithelial cells (Pellon-Cardenas et al., 2013) . To determine whether a similar mechanism drives b-catenin release in uveal melanoma cells, we knocked down CK2a (the catalytic subunit) and determined the intracellular location of b-catenin by subcellular fractionation. CK2a knockdown simultaneously increased b-catenin in the membrane fraction and decreased its localization to the cytoplasm and nucleus ( Figure S3D ), suggesting that a similar ERK-CK2-a-catenin mechanism may control b-catenin release from cadherins in uveal melanoma cells.
b-Catenin signaling can increase cell proliferation in some cancer cells (Clevers, 2006; Reya and Clevers, 2005) . To determine whether b-catenin signaling in uveal melanoma cells influences cell proliferation, we exposed Mel92.1 and Mel202 cells to two different inhibitors of b-catenin signaling, XAV-939 and IWR-1-endo Huang et al., 2009) . After 72 hr of treatment, both XAV939 and IWR-1-endo inhibited cell proliferation in a concentration-dependent manner with a GI 50 (50% growth inhibition) of around 3 mM and 10 mM, respectively, in these cell lines ( Figure S3E ). These results suggest that GNAQ Q209L -ARF6-mediated b-catenin signaling plays a role in uveal melanoma cell proliferation.
Oncogenic GNAQ Forms a Complex with GEP100 to Activate ARF6 We next sought to identify the ARF-GEF responsible for oncogenic GNAQ-mediated ARF6 activation. ARNO and GEP100 are known ARF6-GEFs in endothelial cells and multiple cancer cells (Grossmann et al., 2013; Hu et al., 2012; Morishige et al., 2008; Zhu et al., 2012) , and both ARF-GEFs are expressed in human uveal melanoma tissues ( Figure S4A ). Knockdown of GEP100 ( Figure 4A ), but not ARNO ( Figure S4B ), reduced ARF6-GTP levels by 60% in uveal melanoma cells. Knockdown of GEP100 resulted in 50% inhibition of cell proliferation and 80% inhibition in anchorage-independent colony growth (Figures 4B and 4C) , mimicking the cellular phenotypes of ARF6 knockdown. Similar to the silencing of ARF6 and GNAQ, knockdown of GEP100 also inhibited PLC-PKC, Rac1/RhoA, YAP, and b-catenin signaling, as evidenced by decreased activation of the downstream effectors and reduced nuclear localization and transcriptional activity of YAP and b-catenin ( Figures S4C-S4L ). We hypothesized that oncogenic GNAQ and GEP100 might form a complex that activates ARF6 in uveal melanoma cells, because such complexes have been shown to occur following ectopic expression of Gaq and GEP100 in HEK293T cells (Giguere et al., 2006; Laroche et al., 2007) . Immunoprecipitation of GNAQ from uveal melanoma cells harboring the activating mutation co-precipitated GEP100 ( Figure 4D ), suggesting the existence of a GNAQ Q209L -GEP100 complex.
ARF6 Exerts Its Effect on Constitutive GNAQ Signaling by Controlling GNAQ Q209L Intracellular Localization ARF6 has a known role in endocytosis of GPCRs (Chen et al., 2003; Hunzicker-Dunn et al., 2002) , and GPCRs and Ga proteins are known to traffic between the plasma membrane and early endosomes (Calebiro et al., 2009; Ferrandon et al., 2009; Hynes et al., 2004; Irannejad et al., 2013; Scarselli and Donaldson, 2009; Van Dyke, 2004; Zheng et al., 2004) . To examine whether ARF6 might control activated GNAQ signaling through a similar protein-trafficking mechanism, we knocked down ARF6 in Mel92.1 and Mel202 cells and assessed intracellular localization of GNAQ using both immunocytofluorescence and cell-fractionation analysis. Upon ARF6 silencing, there was an increase in GNAQ localized to the plasma membrane with a concomitant reduction of GNAQ in the cytosol and cytoplasmic vesicles (Figure 5) . GEP100 knockdown likewise exhibited a shift of GNAQ localization from the cytosol and cytoplasmic vesicles to the plasma membrane ( Figures S5A and S5B) . Silencing of other human ARF family members did not cause appreciable intracellular relocalization of GNAQ ( Figure S5C ), thus suggesting that this function is specific to ARF6. Cumulatively, these results suggest that activated ARF6 directs GNAQ to the cytoplasmic vesicles, leading to an increase in signaling of downstream oncogenic pathways.
NAV-2729, a Direct Inhibitor of ARF6, Mimics ARF6 Knockdown in Cell-Function Assays Our finding that ARF6 acts as an immediate downstream effector of the uveal melanoma GNAQ/GEP100 complex that controls all of the currently recognized signaling pathways governed by oncogenic Gaq compelled us to investigate whether chemical inhibitors of ARF6 activation might provide an effective pharmacologic treatment of uveal melanoma. To our knowledge, no direct inhibitors of ARF6 have been published or are commercially available. Therefore, ARF-GEF inhibitors, such as SecinH3, have been used as surrogates for ARF6 inhibition in past studies (Hafner et al., 2006; Grossmann et al., 2013) . However, ARNO, a target for SecinH3 inhibition, promotes epidermal growth factor receptor activation independent of its ARF-GEF activity (Bill et al., 2010) , so inhibiting ARF-GEFs rather than ARF6 directly could lead to off-target effects. Therefore, it is imperative to find direct ARF6 inhibitors that can reduce these unintended consequences. To identify such inhibitors, we devised a highthroughput screen (HTS) based on a fluorometric biochemical assay to identify chemically tractable, reversible, allosteric The requirement for an allosteric, non-nucleotide-competitive mode of action was dictated by intracellular concentrations of GTP, which are approximately 100 mM. A comparative evaluation of more than 20 chemical series and singleton HTS hits from the DIVERSet-EXP collection (Chuprina et al., 2010) of approximately 50,000 compounds (ChemBridge) identified the pyrazolopyrimidinone compound NAV-2729 (Figures 6B and S6) as the most promising ARF6 chemical probe candidate. This compound was selected for further evaluation based on the following properties: (1) low micromolar potency with IC 50 values of 1.0 mM and 3.4 mM determined using fluorometric and orthogonal radiometric ARF6 nucleotide exchange assays, respectively ( Figure 6C ); (2) direct inhibition of ARF6 as evidenced by nearly equipotent inhibitory effects toward spontaneous and ARF-GEF-catalyzed ARF6 nucleotide exchange ( Figure 6D ); (3) a non-nucleotide competitive mechanism supported by the lack of dependence of inhibitory potency on the nucleotide concentration ( Figure 6E ); (4) high selectivity as evidenced by the lack of inhibitory effects for all other human ARF family members, as well as other small GTPases, such as RhoA, Rac1, H-Ras, and Cdc42 at NAV-2729 concentrations up to 50 mM ( Figures  S6D-S6K ); (5) reversible inhibition ( Figure 6F ); and (6) overall chemical tractability including apparent lack of commonly recognized reactive and ''frequent hitter'' functionalities (Baell and Holloway, 2010) .
The proposed direct inhibitory mechanism of NAV-2729 agrees well with the results of molecular docking studies using a structural homology model of the ARF6/ARF-GEF complex ( Figure 6G ). The model predicts association of NAV-2729 with ARF6 in its GEF-binding area, which does not overlap with the nucleotide-binding pocket. A hydrogen bond between the inhibitor carbonyl group and 3-amino group of ARF6 Lys58 residue, as well as the interaction of its nitrophenyl moiety with a hydrophobic pocket formed by aromatic side chains of ARF6 residues Phe47, Trp62, Trp74, and Tyr77, make major contributions to the inhibitor-binding energy ( Figure S6L ). Most importantly, NAV-2729 exhibited a spectrum of biological activities in uveal melanoma cells that are predicted for an ARF6 inhibitor. Treatment of Mel92.1 and Mel202 cells with NAV-2729 inhibited ARF6 activation ( Figure 6H ) and mimicked ARF6 and GEP100 knockdown by driving GNAQ from the cytoplasmic vesicles to the plasma membrane (Figures 6I and 6J) and reducing anchorage-independent colony growth ( Figure 6K ). NAV-2729 also blocked all of the known downstream signaling pathways of oncogenic GNAQ, including PLC/PKC, Rho/Rac, YAP, and b-catenin ( Figure 7 ).
ARF6 Is a Potential Therapeutic Target for Oncogenic GNAQ-Driven Tumors
The finding that the activation state of ARF6 regulates multiple oncogenic GNAQ signaling pathways by controlling the intracellular localization of GNAQ Q209L suggested that ARF6 may be a viable therapeutic target for GNAQ-mediated tumorigenesis. We tested this hypothesis in an orthotopic xenograft mouse model of uveal melanoma. Stable uveal melanoma cells expressing either short hairpin RNAs (shRNA) directed against ARF6 or a non-specific control sequence were generated by lentiviral infection of Mel202 cells. These cells were injected into the posterior vitreous chamber of the eyes of immunocompromised nude mice. Tumor incidence and size were markedly decreased in mice injected with Mel202 cells expressing ARF6 shRNA compared with mice injected with cells expressing control shRNA (Figures 8A and 8B) . Systemic treatment by intraperitoneal injection of the direct ARF6 inhibitor NAV-2729 also significantly reduced uveal melanoma tumor establishment and growth in an orthotopic xenograft mouse model (Figures 8C and 8D) . No signs of toxicity were observed in these studies or in other studies in which the drug was used at the same dosage ( Figure S7 and Tables S1-S3 ). Collectively, these results suggest that the pharmacological inhibition of ARF6 may represent an effective therapeutic approach to the treatment of uveal melanoma and possibly other cancers driven by activating Ga mutations. (B) Subcellular fractionation of GNAQ in Mel92.1 and Mel202 cells following treatment with two independent ARF6 siRNAs and Ctrl siRNA. Individual data points that have been normalized to the control are shown along with geometric means and 95% CIs. 95% CIs that do not cross the dotted line at y = 1 represent significant differences relative to the control at a = 0.05. n = 3. See also Figure S5 .
DISCUSSION
Activated oncogenes such as Ga proteins or members of the RAS superfamily of GTPases act through central signaling nodes, which subsequently trigger multiple molecular events that together induce cancer initiation and invasion (O'Hayre et al., 2014; Pylayeva-Gupta et al., 2011) . Previous studies have shown that activating mutations in either GNAQ or GNA11 promote PLC/PCK and Rac/Rho signaling, leading to both the activation of ERK, p38, JNK, and YAP and subsequent AP-1-and YAP/TEAD-mediated transcription (Feng et al., 2014; Vaque et al., 2013; Wu et al., 2012b; Yu et al., 2014) . Here, we have expanded the number of signaling pathways that are known to be regulated by an activated Gaq protein to include an ARF6-b-catenin pathway in which activated ARF6 promotes the release and subsequent translocation of membrane-bound b-catenin to the nucleus where it induces transcription. By employing biochemical and cellular assays and a newly identified small-molecule inhibitor, we also show that a GNAQ Q209L -GEP100 complex activates ARF6, which functions as an immediate downstream effector to induce the PLC/PKC and Rho/ Rac signaling pathways that lead to AP-1-and YAP/TEAD-mediated transcription ( Figure 8E ). Thus, the activation of ARF6 controls all of the currently known oncogenic pathways mediated by Gaq activating mutations. Our data suggest that activated ARF6 controls GNAQ and b-catenin signaling by regulating protein trafficking between intracellular compartments. Oncogenic GNAQ forms a protein complex with GEP100, which activates ARF6 to promote the redistribution of cell-surface GNAQ to cytoplasmic vesicles. GNAQ signaling appears to primarily occur in these vesicles, because knockdown of ARF6 or GEP100 or chemical inhibition of ARF6 induces the relocalization of GNAQ from the cytoplasm to the plasma membrane with a concomitant decrease in signaling of all GNAQ-mediated pathways. Palmitoylation of GNAQ may contribute to its association with cellular membranes (Wedegaertner et al., 1993) . Although signaling from G proteins such as Ga and RAS proteins have traditionally been thought to occur only at the plasma membrane, more recent studies have challenged this view, suggesting that signaling can also derive from cytoplasmic vesicles (Calebiro et al., 2009; Fehrenbacher et al., 2009; Ferrandon et al., 2009; Hancock, 2003; Hynes et al., 2004; Irannejad et al., 2013; Irannejad and von Zastrow, 2014; Scarselli and Donaldson, 2009; Van Dyke, 2004; Vilardaga et al., 2014; Zheng et al., 2004) . Our data agree with these recent studies but unexpectedly suggest that most of the signaling from active GNAQ in uveal melanoma emanates from cytoplasmic vesicles rather than the plasma membrane. These results, coupled with previous work suggesting that maximal oncogenic H-RAS signaling requires endocytosis and endocytic recycling (Roy et al., 2002) , suggest that the intracellular location of an oncogene may determine its level of activity and that blocking the trafficking of an oncogene to its primary signaling center may effectively diminish its activity. In the case of GNAQ and H-RAS, the primary signaling center appears to be in cytoplasmic vesicles. The activation of ARF6 by oncogenic GNAQ also leads to the release of b-catenin from the plasma membrane and its subsequent transportation to the nucleus, where it induces gene transcription and helps to promote uveal melanoma cell proliferation. This result is consistent with our previous study in cutaneous melanoma, which demonstrated a similar relocalization of b-catenin and increased b-catenin-mediated transcription following stimulation of the FZD4/LRP6 co-receptor complex with WNT5A (Grossmann et al., 2013) .
Our discovery that ARF6 is an immediate downstream effector of the GNAQ Q209L -GEP100 complex suggests that targeting ARF6 with a single small molecule may inhibit all of the currently known Gaq-mediated oncogenic signaling pathways. The necessity and sufficiency of ARF6 activation in orchestrating activated Gaq oncogenic signaling also reveals a strategy to blunt cancer initiation and progression, not just tumor invasion and metastasis. We provide evidence that ARF6 is an actionable node suitable for further development as a therapeutic target by identifying a direct inhibitor of ARF6 that reduces tumor establishment and growth in a xenograft model of uveal melanoma. Uveal melanoma is a devastating cancer and serves as the prototype for activated Ga-protein-mediated cancers. Current treatment relies on surgery and radiation for localized disease, but there is no effective systemic therapy for advanced disease (Harbour, 2012) . The identification of ARF6 as a signaling partner DMSO (vehicle) and are shown along with geometric means and 95% CIs. 95% CIs that do not cross the dotted line at y = 1 represent significant differences relative to the control at a = 0.05. n = 3. See also Figure S6 .
of GNAQ offers a target for treatment regimens that has implications extending beyond Gaq proteins and uveal melanoma to other cancers harboring activated Ga oncogenes, such as pancreatic and biliary cancers (O'Hayre et al., 2013) . Directly targeting certain oncogenes, e.g., activated RAS GTPase, has been challenging (Spiegel et al., 2014; Stephen et al., 2014) , although recent advances have been made (Lim et al., 2014; Ostrem et al., 2013) . Approaches that individually inhibit each arm of an activated oncogenic pathway have been adopted but are inefficient, spurring interest in combination trials as an alternative approach (Thompson, 2013) . By illuminating how a specific activated Ga oncogene orchestrates multiple divergent downstream signaling arms through a single effector, our work suggests that targeting such primary nodal points in the signaling pathways of other GTPases could provide an effective method for combating oncogenesis and tumor establishment.
EXPERIMENTAL PROCEDURES
Detailed protocols for each of the sections below can be found in Supplemental Experimental Procedures.
Cell Lines, Proliferation Assay, and Anchorage-Independent Colony Growth Assay Mel92.1 and Mel202 uveal melanoma cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). HEK293T cells were purchased from the ATCC and maintained in DMEM supplemented with 10% FBS. Cellproliferation assays were performed using CyQUANT (Invitrogen) according to the manufacturer's instructions. Anchorage-independent colony growth was quantified by the CytoSelect 96-Well Cell Transformation Assay (Cell Biolabs) as per the manufacturer's instructions.
RNA Interference, Plasmids, Transfections, Lentiviral Transduction, and qRT-PCR siRNA duplexes (20 nmol) were transfected into uveal melanoma cells using Lipofectamine RNAiMAX (Invitrogen). The coding regions for GNAQ and GNAQ Q209L (Missouri S&T cDNA Resource Center) were cloned into pcDNA3.1 for N-terminal MYC tagging. HEK293T cells were transfected using Lipofectamine LTX (Invitrogen). Mel202 cells were transduced with lentiviruses expressing ARF6 shRNA (Sigma) and selected for stable expression. Rescue experiments were performed as described in Supplemental Experimental Procedures. qRT-PCR was performed with the Applied Biosystems 7900HT and QuantiTect SYBR Green PCR kit (Qiagen).
ARF6/RhoA/Rac1 Pull-Downs, Immunoblots, Immunoprecipitation, Cell Fractionation, PLC Assay, Luciferase Assay, and Immunofluorescence Staining ARF6-GTP pull-downs were performed with the Arf6 Activation Assay Kit (Cell Biolabs) and Rac1/RhoA-GTP pull-downs were prepared with the Rac1 Activation Assay Kit/RhoA Activation Assay Kit (Millipore) according to the manufacturer's instructions. Immunoprecipitation was performed as previously described (Grossmann et al., 2013) . For immunoblotting, primary antibodies were diluted in 5% non-fat dry milk or 5% BSA in PBS or Tris-buffered saline (TBS) plus 0.1% Tween 20 and incubated overnight at 4 C. Plasma membrane or total membrane fraction was isolated with the Plasma Membrane Protein Extraction Kit (Abcam) and cytosolic/nuclear fractions were prepared with NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific) according to the manufacturer's instructions. All antibodies for immunoblots, immunoprecipitation, and immunocytofluorescence staining are listed in table format in Supplemental Experimental Procedures. Scanning densitometry was used for immunoblot quantification. b-Catenin-and AP-1-mediated transcriptional activities in uveal melanoma cells were assayed using lentivirally transduced cells that stably express the TOPflash-based 7TFP luciferase reporter (Addgene) (Fuerer and Nusse, 2010) or AP-1 luciferase reporter (Qiagen). PLC activity was determined using a phosphoinositide turnover assay as described by others . For immunofluorescence staining studies, Mel202 and Mel92.1 cells were transfected with ARF6, GNAQ, and control siRNAs and later fixed with formalin, then thoroughly washed with TBS. The fixed cells were treated with primary antibodies overnight at 4 C in TBS containing 1% BSA and 0.1% saponin. Cells were washed, and secondary Alexafluor-conjugated secondary antibody was applied for 1 hr at room temperature. The cells were washed, DAPI anti-fade medium was added, and randomly selected fields were imaged at 1,2003 on an Olympus FV1000 confocal microscope.
Human Uveal Melanoma Patient Samples
These studies were done in accordance with a protocol approved by the University of Miami Institutional Review Board, and informed consent was obtained from all patients. Primary human uveal melanoma samples were collected at the time of enucleation as previously described (Onken et al., 2007) .
Orthotopic Xenograft Mouse Model of Uveal Melanoma
All animal studies were performed in accordance with a protocol approved by the University of Utah Institutional Animal Care and Use Committee. Nude mice were anesthetized and 10 5 Mel202 cells were injected into the posterior chamber of the eye. For systemic small-molecule treatment, intraperitoneal injections of either 30 mg/kg NAV-2729 or control DMSO were provided each day. At 5 weeks, the mice were euthanized and the eyes were collected and treated for histology by a board-certified pathologist who was blinded to treatment groups.
Recombinant Protein Expression and Purification
His-tagged proteins were purified from bacterial cultures to apparent homogeneity as described by Grossmann et al. (2013) . ARF6 was converted to the guanosine diphosphate (GDP)-bound form.
Toxicity Studies For details, see Supplemental Experimental Procedures.
Fluorometric Nucleotide Exchange Assay GDP-to-GTP exchange on ARF6 and other small GTPases was monitored in a 96-well format HTS using GTP-BODIPY FL (Life Technologies) by measuring increases in fluorescence intensity on a plate reader (excitation 490 nm and emission 520 nm). A DIVERSet-EXP library of compounds (ChemBridge) was used at 10 mM. The selectivity panel included eight other N-terminallytagged small GTPases that were produced in-house or purchased from Cytoskeleton.
Radiometric Nucleotide Exchange Assay HTS hits were confirmed using a radiometric assay for ARF6 nucleotide exchange in an assay mix similar to that used in the fluorimetric nucleotide The graph shows individual data points normalized to control along with geometric means and 95% confidence intervals (95% CI). 95% CIs that do not cross the dotted line at y=1 represent significant differences relative to the control at α=0.05. n=4. (C) Immunoblot of lysates prepared from Mel202 cells transfected with empty vector or MYC-ARF6 Q67L and treated with Control (Ctrl) or GNAQ siRNAs. Knockdown of GNAQ and expression of endogenous (wild-type) and ectopic (MYC-ARF6 Q67L ) ARF6 were evaluated by immunoblotting. Actin was used as a loading control. Knockdown of GNAQ and ectopic expression of ARF6 Q67L were checked for each of the three proliferation and anchorage-independent colony growth experiments shown in panels D and E. (D) Cell proliferation as monitored by DNA content using CyQUANT reagent and a fluorescent microplate reader. Mel202 cells were treated as described for panel C. n=3. (E) Anchorage-independent colony growth as monitored microscopically and by DNA content using CyQUANT reagent and a fluorescent microplate reader. Mel202 cells were treated as described for panel C. Scale bar: 1000 µm. For panels D and E, data are represented as mean + SD, n=3 experiments. One-way ANOVA, Tukey's multiple comparisons test, *p<0.05, **p<0.01, ***p<0.001. Figure 2 . For panels B, D, and F, the data are represented as mean + SD, n=3 experiments. One-way ANOVA, Dunnett's multiple comparisons test, ***p < 0.001. For panels C, E, and G-N, the graphs show individual data points normalized to control along with geometric means and 95% confidence intervals (95% CI). 95% CIs that do not cross the dotted line at y=1 represent significant differences relative to the control at α=0.05. n=3 to 5 as indicated. For panels A and B, the graphs show individual data points normalized to control along with geometric means and 95% confidence intervals (95% CI). 95% CIs that do not cross the dotted line at y=1 represent significant differences relative to the control at α=0.05. n=3. For panels B, D-G, I , and K, the graphs show individual data points normalized to control along with geometric means and 95% confidence intervals (95% CI). 95% CIs that do not cross the dotted line at y=1 represent significant differences relative to the control at α=0.05. n=3 to 5 as indicated. For panels C, H, J, and L, the data are represented as mean + SD, n=3 experiments. One-way ANOVA, Dunnett's multiple comparisons test, ***p < 0.001. The graph shows individual data points normalized to control along with geometric means and 95% confidence intervals (95% CI). 95% CIs that do not cross the dotted line at y=1 represent significant differences relative to the control at α=0.05. n=3. (C) Mel 92.1 and Mel202 cells were exposed to siRNAs against ARF3, ARF4, ARF5, or ARF6, and subcellular localization of GNAQ was monitored by immunofluorescence. Only ARF6 knockdown drives GNAQ localization towards the plasma membrane. ARF1 expression is required for cell viability and therefore its effect on GNAQ localization cannot be assessed. Humans do not possess an ARF2 gene. Scale bar = 30 µm. (C) Survival curve shows that all mice survived during a 14-day dosing regimen, except for 3 out 10 mice that received the highest dosage of NAV-2729 (60 mg/kg, BID). The key is for both panels B and C. (D) No significant lesions were found in tissues from five major organs collected from C57BL/6J mice that had received daily intraperitoneal injections of 30 mg/kg NAV-2729 (left column). Likewise, no significant lesions were observed in mice that received 30 mg/kg, BID or 60 mg/kg in a single daily injection (see Table S3 ). However, a large region of necrosis is located in the center of the image of the liver section taken from a mouse that received 60 mg/kg of NAV-2729, BID (right column). Also, the lungs show signs of pneumonia with acute inflammation marked by interstitial neutrophils. Scale bars are shown for each image. *nd = not determined, because mouse died at day 7. BID = Twice daily. WBC = White Blood Cell count. RBC = Red Blood Cell count; HCT = Hematocrit; PLT = Platelet count. Red font = high. Blue font = low.
Figure S2. Related to Figure 2. Quantitation of western blots; Ectopic expression of constitutively active ARF6 (ARF6 Q67L ) in HEK293T cells activates downstream oncogenic GNAQ signaling pathways. (A-H) Quantitation of the activation of MARCKS (G), Rac1 (H), RhoA (I), ERK (J), p38 (K), JNK (L), c-jun (M), and the subcellular localization of YAP (N) from the immunoblots shown in
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Cell lines, proliferation assay, and anchorage-independent colony growth Mel92.1 and Mel202 uveal melanoma cells were originally obtained from Martine Jager and subsequently characterized in the S.E. Woodman laboratory (Griewank et al., 2012) . Mel92.1 and Mel202 uveal melanoma cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). HEK293T cells were purchased from ATCC and maintained in DMEM supplemented with 10% FBS. Cell proliferation assays were performed using CyQUANT (Invitrogen) according to the manufacturer's instructions. 5 × 10 3 uveal melanoma cells were plated into each of three or four wells of a 96-well plate and fluorescence was measured 4 hr later after cell attachment to obtain baseline measurements and at 72 h as endpoint measurements. Anchorage-independent colony growth was quantified by the CytoSelect 96-Well Cell Transformation Assay (Cell Biolabs) as per manufacturer's instructions. After 12-15 days, relative colony size/number was confirmed by microscopic examination and measured by adding CyQUANT reagent to the cultures and measuring fluorescence using a plate reader at excitation/emission wavelengths of 485/530 nm.
RNA interference, plasmids, transfections, lentiviral transduction, qRT-PCR, and chemicals All siRNAs, shRNAs, and primer sequences for qRT-PCR are listed in the table below. siRNA duplexes (20 nmol) were transfected into uveal melanoma cells using Lipofectamine RNAiMAX (Invitrogen). Plasmids for wild-type GNAQ and GNAQ Q209L were obtained from Missouri S&T cDNA Resource Center. The coding regions of both constructs were re-cloned into pcDNA3.1 vector for MYC epitope-tagging at the N-terminal. For ectopic expression in HEK293T, cells were seeded in 10-cm plates and transfected with the respective plasmids using Lipofectamine LTX (Invitrogen). Lentiviruses containing control and ARF6 shRNA expression constructs were purchased from Sigma and were used to infect Mel202 uveal melanoma cells. Infected cells were selected using 1 µg/ml of puromycin (Invitrogen) for 5 days. For rescue experiments by ARF6 Q67L during GNAQ knockdown, Mel202 uveal melanoma cells were transfected with pcDNA3.1 as a vector control or ARF6 Q67L plasmid (Grossmann et al., 2013 ) and selected with G418 (800 µg/ml; Gibco) for 7 days before transfection with siRNA against GNAQ. qRT-PCR was performed with the Applied Biosystems 7900HT and QuantiTect SYBR Green PCR kit (Qiagen) with the primers listed in the table below. IWR-1-endo and XAV-939 were purchased from Calbiochem. The same procedure was also performed on untransfected Mel92.1 and Mel202 that were treated either with 5 µM NAV-2729/0.1% DMSO or 0.1% DMSO alone (control) for 1 hr before being fixed and imaged as described above.
RNAi and primer sequences used in this study
Human uveal melanoma patient samples
Primary human uveal melanoma samples were collected and snap frozen at the time of enucleation as previously described (Onken et al., 2007) . All samples were confirmed to be uveal melanomas by pathologic evaluation. Normal choroid tissues were also collected from selected enucleated eyes and melanocytes were isolated from these tissues, cultured for 1-3 passages, and frozen as previously described (Matatall et al., 2013) . These latter samples served as controls for ARF6 expression analysis. Samples were homogenized and lysed with ice-cold lysis buffer.
Lysates were centrifuged for 20 min at 14,000 rpm and the supernatants were used to determine protein concentrations by BCA assays (Pierce). 15 µg of lysates were carefully loaded into each well of the gel to generate the immunoblots.
Orthotopic xenograft mouse model of uveal melanoma
All animal studies were performed in accordance with a protocol approved by the University of Utah Institutional Animal Care and Use Committee. Athymic nude mice were purchased from Jackson Laboratories for this study. Mice were anesthetized with an intraperitoneal injection of a mixture of ketamine and xylazine. The eye was viewed under a dissecting microscope, and a sterile 30-gauge needle was used to puncture the posterior chamber of eye. 10 5 cells in 5 µl were injected into the eye with a Hamilton syringe. For systemic treatment of NAV-2729, the compound was administered daily by intraperitoneal injection of 30 mg/kg over a period of 5 weeks starting on the day of cell injection. After 5 weeks of tumor growth, mice were euthanized with CO 2 , and eyes were collected, fixed, embedded, sectioned, stained with H&E, and examined histologically for primary tumors by a pathologist who was blinded to the treatment regimen.
Recombinant Protein Expression and Purification
All recombinant proteins for the assay development for ARF family members were produced as N-terminally Histagged fusions in E. coli cultures and purified to apparent homogeneity as described previously (Grossmann et al., 2013) , including the truncated forms of ARF6 (14-175), ARF1 (18-181), ARF3 (18-181), ARF4 (18-180), and ARF5 (18-180), which do not require membranes or lipid vesicles for full activity, as well as the Sec7 domaincontaining fragments of GEP100 and ARNO that encompass residues 391-602 and 50-255, respectively. The recombinant ARF proteins purified in 50 mM Tris-HCl, pH 7.8, 100 mM NaCl, 2 mM MgCl 2 , 10% glycerol, 2 mM β-mercaptoethanol and approximately 150 mM imidazole were routinely converted into GDP-bound form by 2-h incubation in the presence of 5 mM EDTA and GDP in 10-fold molar excess relative to the ARF proteins. Upon addition of MgCl 2 to 20 mM to terminate nucleotide exchange, two rounds of ultrafiltration, using Amicon Ultra-15-10K centrifugal filter units, were performed to remove free nucleotide and replace buffer system with 50 mM TrisHCl, pH 7.5, 100 mM NaCl, 2 mM MgCl 2 , 10% glycerol, 2 mM β-mercaptoethanol.
Toxicity Studies C57BL/6J, DBA/1J, or nude mice (J:NU) were administered NAV-2729 by intraperitoneal injection at dosages ranging from 10 mg/kg daily to 60 mg/kg BID (twice daily) over different time courses (14-35 days) and monitored for survival, weight loss/gain, blood cell counts, hematocrit, and/or histopathological changes of the liver, lungs, heart, kidney, and brain. Blood and histopathological analyses were performed by the national veterinary reference laboratories IDEXX Preclinical Research Services (West Sacramento, CA) and Animal Reference Pathology (Salt Lake City UT), respectively.
Fluorometric Nucleotide Exchange Assay
Our fluorometric nucleotide exchange assay for ARF6 and other small GTPases exploits fluorogenic nucleotide probe, GTP labeled with BODIPY FL, for monitoring GDP-to-GTP exchange at the nucleotide-binding site of ARF6. Intrinsic fluorescence of GTP-BODIPY is intramolecularly quenched in the unbound state but is significantly increased upon its binding to the target protein such as ARF6 or other small GTPases (McEwen et al., 2001 ). The fluorometric ARF6 nucleotide exchange assay used for high-throughput screening and routine inhibition assays was carried out in 96-well format using 100-µl aliquots of 50 mM Tris-HCl, pH 7.5, 1 mM MgCl 2 , 0.01% Triton X-100, 2 mM β-mercaptoethanol, 1% DMSO, 50 nM GTP-BODIPY FL, 25 nM ARNO or GEP100, and 200 nM ARF6•GDP (unless indicated otherwise). Replacement of ARF6-bound GDP by GTP-BODIPY FL was monitored by measuring increases in fluorescence intensity during a 30-60 minute time course using a plate reader at the excitation and emission wavelengths of 490 nm and 520 nm, respectively. The high-throughput screening was performed at the University of Utah Drug Screening Resource using DIVERSet-EXP library of compounds (ChemBridge) at 10 µM concentrations. The selectivity tests were conducted in the same format using small GTPases at 200 nM concentrations. Similar to ARF6, all other ARF proteins produced in-house were tested for inhibition in the presence of 25 nM ARNO. Other members of the selectivity panel, namely, RhoA, Rac1, Cdc24, and H-Ras that represent bacterially expressed N-terminally His-tagged full-length recombinant proteins were purchased from Cytoskeleton, Inc., and tested for inhibition of spontaneous nucleotide exchange in the absence of any GEF. GTP-BODIPY FL was provided by Life Technologies. A non-homogeneous version of the above nucleotide exchange assay was employed to assess the mode of ARF6 inhibition with respect to fluorogenic nucleotide. In this case, the recombinant ARF6 was immobilized via its His-tag on the surface of nickel-coated 96-well plates followed by performing nucleotide exchange reaction in the absence or in the presence of NAV-2729 under otherwise standard conditions using GTP-BODIPY FL at the concentrations indicated on Figure 6E . At the end of the reaction period, the microtiter wells were washed three times with both protein-and nucleotide-free assay buffer followed by fluorometric quantification of GTP-BODIPY FL bound to ARF6 as described above. For the determination of signal-to-background ratio (S:B) and Z'-factor, the assay was performed using a 96-well plate with half of the wells supplemented with 10 µM GDP to estimate background fluorescence (B), which is equivalent to mean negative control value (µn), and another half with DMSO control to determine signal intensity (S), which is equivalent to mean positive control value (µp). Z' factor value was calculated using the following formula: Z'=1 -3(σp + σn)/(µp -µn), which also includes standard deviations for the positive and negative controls (σp and σn, respectively).
Radiometric Nucleotide Exchange Assay
The confirmation of HTS hits using a radiometric assay for ARF6 nucleotide exchange was carried out using 100-µl aliquots of same assay mix specified above for the fluorometric technique with the exception that 50 nM [ 35 S]-GTPγS (2 µCi/ml) was included to replace GTP-BODIPY FL. Upon incubation for 30 minutes in the presence of test articles, 200 µl of ice-cold assay buffer supplemented with 10 mM MgCl 2 was added to stop the reaction followed by a rapid vacuum filtration of the samples using a nitrocellulose-bottomed 96-well plate, three washes of the membrane with the above stop solution, and scintillation counting to quantify GTPγS bound to ARF6.
Synthetic Methods
All solvents and reagents were purchased from commercial sources and used without further purification unless otherwise noted. Reactions were monitored by TLC (thin layer chromatography) using 0.25 mm silica gel 60 F254 plates purchased from EMD chemicals. Purification was performed with Teledyne ISCO CombiFlash Rf. 1 H NMR and 13 C spectra were recorded on a Varian Mercury 400 MHz instrument. Proton chemical shifts are expressed in parts per million (ppm) relative to TMS and calibrated using residual undeuterated solvent as internal reference. High-resolution mass spectra (HRMS) were recorded on Finnigan LTQ-FT, Thermo Electron Corporation. Compound purity was determined by an Agilent HP1050 instrument with a 4.6 mm × 150 mm Xterra C18 3.5 µm column. The flow rate was 1.2 mL/min, and the injection volume was 10 µl. HPLC conditions were as follows: mobile phase A, HPLC grade water (0.01% TFA); mobile phase B, HPLC grade acetonitrile (0.01% TFA); UV detector, 254 nm; 95% A/5% B to 0% A/100% B in 10 min, 100% B in 10−11 min, 100% B to 95% A/5% B in 11−13 min, 95% A/5% B in 13−15 min. The final compound was ≥95% pure by HPLC. [1,5-a]pyrimidin-7-one (NAV-2729) is described in Scheme shown below. First, we synthesized 3-Benzyl-4-(4-chlorophenyl)-1 H-pyrazol-5-amine as follows. To a solution of 2-(4-chlorophenyl)acetonitrile (15.0 g, 98.95 mmol) in THF was added NaH (60%) (4.73 g, 118.38 mmol) portionwise at room temperature. To the above mixture initially 2 mL of ethyl 2-phenylacetate was added and the mixture was warmed to 40 o C for 10 min. It was cooled in an ice bath, and after the initiation of the reaction, the remaining ethyl 2-phenylacetate (15.35 mL), a total of 17.35 mL (108.84 mmol), was added dropwise. The ice bath was removed and stirring continued at room temperature for 3.5 h. At the end of this period the reaction mixture was quenched with aqueous NH 4 Cl solution (20 mL) and the pH was adjusted to 3 by adding 3N HCl. The mixture was partitioned with ethyl acetate (150 mL). The aqueous layer was extracted with ethyl acetate (50 mL). The combined ethyl acetate layer was washed with brine, dried (Na 2 SO 4 ), filtered and solvent was evaporated to dryness under reduced pressure to afford 2-(4-chlorophenyl)-3-oxo-4-phenyl-butanenitrile in quantitative yield. This product was used for the next step without further purifications. The crude 2-(4-chlorophenyl)-3-oxo-4-phenylbutanenitrile was dissolved in toluene (150 mL). To the above solution was added acetic acid (31.12 mL, 544.22 20 mmol) followed by hydrazine hydrate (14.40 mL, 296.85 mmol) dropwise. The reaction mixture was refluxed for 16 h. At the end of this period, it was cooled to room temperature and solvent and excess reagents were removed under reduced pressure. The residue was neutralized with saturated NaHCO 3 solution, and the separated solid was filtered and washed with water (3x50 mL) and dried under vacuum at 50 o C for 10h to afford title product (22.0 g, 78%). 1H-NMR (400 MHz, J= 8.4 Hz, 2H), 4H), 1H), 7.04 (d, J= 8.5, 2H) , 4.57 (bs, 2H), 3.87 (s, 2H). 3-benzyl-4-(4-chlorophenyl)-1H-pyrazol-5-amine and ethyl 3-(4-nitrophenyl)-3-oxo-propanoate were then refluxed in acetic acid for 16 h. Figure S6N) δ 32. 5, 96.4, 123.4, 126.1, 128.2, 128.4, 129.3, 129.7, 131.7, 131.8, 138.5, 148.6, 155.6 
Synthesis of 2-benzyl-3-(4-chlorophenyl)-5-(4-nitrophenyl)-4H-pyrazolo
Molecular Modeling
Molecular modeling was performed using program package ICM-Pro (MolSoft, LLS, San Diego, CA) that includes modules for homology modeling, docking and virtual ligand screening. Homology model of N-terminally truncated ARF6 (Δ13) structure was built using ARF1 (Δ17) template extracted from a crystal structure of ternary ARF1 (Δ17)-GDP ARNO complex with inhibitor brefeldin A (Protein Data Bank ID 1S9D) (Renault et al., 2003) . Then ARF1 structure in the ternary complex was replaced with the homology model of ARF6 and brefeldin A (BFA) was removed from the complex. Inhibitor NAV-2729 was docked into a binding site at the interface between ARF6 and ARNO. The preliminary model of ARF6-ARNO complex with NAV-2729 was refined using a binding site side chain optimization procedure available with ICM-Pro program.
Statistical analyses
Statistical analyses were performed using GraphPad Prism 6.0f. When two groups were being compared and the data appeared to be normally distributed and the variances were approximately equal, the Student's t test was used. Welch's correction was applied when the variances were not equal or the number of data points was significantly different. When multiple t tests were performed on groups of similar data, a Holm-Sidak multiple t test analysis was used. When multiple treatment groups were being compared to a single control and the data were normally distributed, one-way ANOVA with Dunnett's multiple comparisons test was performed. When multiple groups were being compared and each group was compared to all other groups and the data were normally distributed, one-way ANOVA with Tukey's multiple comparisons test was performed. When the data did not appear to be normally distributed, the Mann-Whitney U test was used. For categorical data where two treatment groups are classified by two different outcomes, Fisher's exact test was used. For statistical analyses of immunoblots, the density of each band was normalized to an internal control protein and then the ratio of the normalized density of the band from the experimental treatment to the normalized density of the paired control treatment band was obtained. Because these values are ratios, geometric means and 95% confidence intervals were calculated and the ratios were plotted on a logarithmic scale to determine significance.
